If this expert is right, the market is in for a big drop this summer.
Read MoreOf all the big names that helped push the Nasdaq to that big, round number, there’s 1 stock in the bunch that still looks like a winner for the long-term.
Read MoreThis expert says investors should think hard before jumping in on the market’s recent rally.
Read MoreWhile the investing legend is bearish on growth stocks in general, Druckenmiller says he’s still a buyer of these 2 stocks.
Read MoreAfter selling his company for billions, he went “all in” on just these 2 stocks, and only has one regret.
Read MoreVolatility appears to be returning to the markets this week, as concern is increasing about a second wave of COVID-19 infections. Yesterday Fed chair Jerome Powell announced the Fed was planning to keep rates at or near zero through 2022 to support economic recovery following a near-complete shutdown of U.S. business activity in an effort […]
Read MorePlus, Treasury Secretary Mnuchin said “we can’t shut down the economy again” for a second wave, weekly jobless claims came in at more than 1.5 million, and Regeneron said it started the first clinical trial of its coronavirus antibody treatment.
Read MoreBuy Price: $3.25 or better Sell Price: TradersPro Sell Signal NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including […]
Read More